RU2012114854A - Способы лечения псориаза - Google Patents

Способы лечения псориаза Download PDF

Info

Publication number
RU2012114854A
RU2012114854A RU2012114854/15A RU2012114854A RU2012114854A RU 2012114854 A RU2012114854 A RU 2012114854A RU 2012114854/15 A RU2012114854/15 A RU 2012114854/15A RU 2012114854 A RU2012114854 A RU 2012114854A RU 2012114854 A RU2012114854 A RU 2012114854A
Authority
RU
Russia
Prior art keywords
individual
antibody
weeks
psoriasis
dose
Prior art date
Application number
RU2012114854/15A
Other languages
English (en)
Russian (ru)
Inventor
Хоакин Марио ВАЛЬДЕС
Эллиот К. ЧАРТАШ
Уилльям Т. БАРЧУК
Сьюзан К. ПОЛСОН
Кеннет В. ГОРДОН
Валид М. АВНИ
Яньжунь БАО
Уилльям Дж. ГЛАСС
Ихуа ГУ
Том К. ХАРРИС
Мартин КАУЛ
Парвез М. МУЛАНИ
Петер НЕРТЕРСХОЙЗЕР
Мартин М. ОКУН
Original Assignee
Эбботт Лэборетриз
Эбботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Лэборетриз, Эбботт Гмбх Унд Ко. Кг filed Critical Эбботт Лэборетриз
Publication of RU2012114854A publication Critical patent/RU2012114854A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2012114854/15A 2009-09-14 2010-09-14 Способы лечения псориаза RU2012114854A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24228809P 2009-09-14 2009-09-14
US61/242,288 2009-09-14
US24596709P 2009-09-25 2009-09-25
US61/245,967 2009-09-25
US29762310P 2010-01-22 2010-01-22
US61/297,623 2010-01-22
US36029910P 2010-06-30 2010-06-30
US61/360,299 2010-06-30
PCT/US2010/048771 WO2011032148A1 (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
RU2012114854A true RU2012114854A (ru) 2013-10-27

Family

ID=43732849

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012114854/15A RU2012114854A (ru) 2009-09-14 2010-09-14 Способы лечения псориаза

Country Status (15)

Country Link
US (2) US8557239B2 (https=)
EP (1) EP2477654A4 (https=)
JP (1) JP2013504598A (https=)
KR (2) KR20120112384A (https=)
CN (1) CN102630168A (https=)
AU (1) AU2010291927A1 (https=)
CA (1) CA2773556A1 (https=)
IL (1) IL218633A0 (https=)
IN (1) IN2012DN01965A (https=)
MX (1) MX2012003138A (https=)
NZ (1) NZ598722A (https=)
RU (1) RU2012114854A (https=)
SG (1) SG179135A1 (https=)
TW (1) TW201127400A (https=)
WO (1) WO2011032148A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
EP2734236A4 (en) * 2011-07-13 2015-04-15 Abbvie Inc METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
AU2017332771A1 (en) * 2016-09-23 2019-04-04 Abbvie Inc. Dose adjustment
IL274272B2 (en) 2017-11-06 2025-09-01 Janssen Biotech Inc A safe and effective method for treating psoriatic arthritis with a specific anti-IL23 antibody
RU2697415C1 (ru) * 2018-11-12 2019-08-14 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения каплевидного псориаза
CN113015531A (zh) 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
JP7272557B2 (ja) * 2020-12-24 2023-05-12 国立大学法人神戸大学 紫外線照射を用いたウイルス不活化方法
BR112023018400A2 (pt) * 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
MX2023010705A (es) * 2021-03-12 2023-11-22 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
AU2024262868A1 (en) * 2023-04-26 2025-11-06 Innovent Biologics (Suzhou) Co., Ltd. Method for treating psoriasis with recombinant interleukin 23p19 antibody

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) * 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0494955T3 (da) * 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6683046B1 (en) * 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ES2159529T5 (es) * 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
WO1998016248A1 (en) 1996-10-11 1998-04-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
PT936923E (pt) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1999037682A2 (en) * 1998-01-23 1999-07-29 F.Hoffmann-La Roche Ag Antibodies against human il-12
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
JP3579355B2 (ja) * 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
SI2168984T1 (sl) * 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
CA2492143A1 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
CN100522998C (zh) * 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
EP1694317A4 (en) * 2003-12-19 2010-05-12 Protemix Corp Ltd COPPER ANTAGONIST COMPOUNDS
RU2390353C2 (ru) * 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
SG158150A1 (en) * 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
AU2006265002B2 (en) * 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
CA2681752A1 (en) * 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
TW201309330A (zh) * 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途

Also Published As

Publication number Publication date
JP2013504598A (ja) 2013-02-07
WO2011032148A1 (en) 2011-03-17
NZ598722A (en) 2014-05-30
CA2773556A1 (en) 2011-03-17
IN2012DN01965A (https=) 2015-08-21
US8557239B2 (en) 2013-10-15
EP2477654A1 (en) 2012-07-25
SG179135A1 (en) 2012-05-30
MX2012003138A (es) 2012-07-04
TW201127400A (en) 2011-08-16
EP2477654A4 (en) 2013-01-23
US20110206680A1 (en) 2011-08-25
IL218633A0 (en) 2012-05-31
CN102630168A (zh) 2012-08-08
KR20140048229A (ko) 2014-04-23
KR20120112384A (ko) 2012-10-11
US20140079714A1 (en) 2014-03-20
AU2010291927A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
RU2012114854A (ru) Способы лечения псориаза
Uhlig et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome
Berntson et al. Cardiac autonomic balance versus cardiac regulatory capacity
McDonald et al. Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant α-interferon in hepatitis-B carriers
Lam et al. Improving glycaemic and BP control in type 2 diabetes: the effectiveness of tai chi
RU2020109345A (ru) Применение мавакамтена для лечения гипертрофической кардиомиопатии
US20230303678A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
RU2013120322A (ru) Способы лечения псориаза
CN102458376A (zh) 多巴胺激动剂加上第一时相胰岛素促分泌剂的组合物用于治疗代谢失调
Medved et al. Takotsubo cardiomyopathy after the first electroconvulsive therapy regardless of adjuvant beta-blocker use: a case report and literature review
Jun-Chi et al. Successful treatment of paediatric morphea with tofacitinib
Kurtzhals et al. The role of weight control in the management of type 2 diabetes mellitus: perspectives on semaglutide
US20080279819A1 (en) Combinations Therapy for Treatment of Demyelinating Conditions
US5378686A (en) Therapeutic treatment of fibromyalgia
Kanamasa et al. Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients
Cozzolino et al. Acute pressor and hormonal effects of β-endorphin at high doses in healthy and hypertensive subjects: role of opioid receptor agonism
Ahmed et al. Is testosterone replacement safe in men with cardiovascular disease?
Collins et al. Improvement in angina pectoris with alpha adrenoceptor blockade.
Zeng et al. Atorvastatin improves the cardiac function of rats after acute myocardial infarction through ERK1/2 pathway.
Aichhorn et al. Cardiomyopathy after long-term treatment with lithium–more than a coincidence?
Nekrasov et al. The effect of rivaroxaban low doses on the stable angina of the II-III functional class clinical manifestations and the quality of life in patients with ischemic heart disease
Navinés et al. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders
Sands et al. The Rise of GLP-1 Agonists: A Review of Their Role in Weight Man-agement and Obesity Treatment
US20210213104A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
Altai et al. Levothyroxine Induced Flash Pulmonary Edema

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant